id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1690-0006,FDA,FDA-2013-E-1690,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-12-08T05:00:00Z,2015,12,2015-12-08T05:00:00Z,,2015-12-08T14:17:38Z,,0,0,0900006481d8cd30
FDA-2013-E-1690-0005,FDA,FDA-2013-E-1690,"Determination of Regulatory Review Period for Purposes of Patent
Extension; SYNRIBO",Notice,Determinations,2015-05-07T04:00:00Z,2015,5,2015-05-07T04:00:00Z,2015-11-04T04:59:59Z,2015-05-07T15:59:45Z,2015-11004,0,0,0900006481ad294e
FDA-2013-E-1690-0004,FDA,FDA-2013-E-1690,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-04-23T04:00:00Z,2015,4,2015-04-23T04:00:00Z,,2015-04-23T12:53:50Z,,0,0,0900006481ab5ed5
FDA-2013-E-1690-0003,FDA,FDA-2013-E-1690,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-01-31T05:00:00Z,2014,1,2014-01-31T05:00:00Z,,2014-01-31T12:24:11Z,,0,0,0900006481538bf3
FDA-2013-E-1690-0002,FDA,FDA-2013-E-1690,"CEPHALON, Inc. -  Patent Term Application",Other,Application,2013-12-26T05:00:00Z,2013,12,2013-12-26T05:00:00Z,,2013-12-26T13:38:09Z,,0,0,09000064814db6fc
FDA-2013-E-1690-0001,FDA,FDA-2013-E-1690,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-12-26T05:00:00Z,2013,12,2013-12-26T05:00:00Z,,2013-12-26T13:38:00Z,,0,0,09000064814db6fd